Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6243233 | 0.81 | KMT2A (0.55) | KMT2ASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL4764015 | 0.77 | KMT2A (0.69) | KMT2ASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL4864080 | 0.77 | TYMS (0.48) | KMT2ASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL4762572 | 0.76 | ALDH1A1 (0.63) | KMT2AMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL4769449 | 0.76 | KMT2A (0.44) | KMT2ASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL5801672 | 0.72 | L3MBTL1 (0.59) | KMT2AMEN1POLBATM | |
| SCHEMBL4767367 | 0.70 | HSPD1 (0.41) | KMT2ASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL4771370 | 0.70 | ALDH1A1 (0.53) | KMT2ASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL9420347 | 0.70 | KMT2A (0.52) | KMT2AMEN1ALDH1A1POLBHPGD | |
| SCHEMBL11378716 | 0.70 | BRAF (0.44) | KMT2AMEN1ALDH1A1MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | KMT2A 1806/4885SMN1; SMN2 3995/4885MEN1 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.